Elsewhere on Ulster
This project is funded by:
Background: Microbubbles are routinely employed in the clinic as ultrasound contrast agents, and they function by stably oscillating in an ultrasonic field to delivery echogenic signals that enhance the ultrasound image.
It has been shown that higher acoustic pressures can be used to ‘pop’ the bubbles and emerging evidence continues to demonstrate promise in facilitating targeted delivery of therapeutics [1]. Such approaches offer significant benefit to patients receiving cancer chemotherapeutics since the approach offers the possibility of depositing the toxic drug at the target tumour and precludes deposition at off target sites which can lead to very significant adverse effects.
In addition, microbubble-based approaches can be seamlessly integrated with emerging therapeutic approaches in oncology (e.g. immunotherapy) [2].
However, applicability of microbubble-based approaches is limited by the amount of payload that can be accommodated by such vehicles, and this has been conventionally addressed by using very potent therapeutic drugs and/or exploiting microbubble designs that incorporate a drug reservoir (e.g. using a drug compatible solvent that forms an integral part of the microbubble construct).
SonoTarg Ltd., an Ulster University spin out company, has designed an acoustically responsive microbubble construct that (1) incorporates a drug reservoir to accommodate increased drug concentrations and (2) leverages the presence of a sonodynamic agent that increases the sensitivity of the target to the drug accommodated in that reservoir [3].
This project seeks to define the utility and flexibility of the basic microbubble platform by incorporating a diverse range of emerging therapeutic agents into the reservoir with a view towards developing novel therapeutic approaches for cancer.
This strategy will serve to (1) identify novel, more effective therapeutic drug combinations that increase efficacy and reduce adverse effects, (2) rationalize clinical translation and (3) enhance commercial exploitation.
Underlying aim: To explore the use of a number of emerging oncology drug combinations with an acoustically responsive microbubble-based platform.
Specific Objectives:
1. To prepare a range of microbubble formulations accommodating emerging cancer therapy drugs.
2. To characterize each formulation in terms of size, drug content, stability and response to ultrasound.
3. To characterize each formulation in terms of stimulus responsive efficacy and toxicity in the presence and absence of stimulus using in vitro approaches.
4. To explore efficacy of formulations using a range of tumour models in vivo.
Please note: Research Proposal - 5 pages in total
The proposal must include:
Please also note that the use of AI in generating the research proposal is prohibited.
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Biomedical Sciences/Pharmacy and Pharmaceutical Sciences, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission.
If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship.
In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
PhD Scholarships are available for this project and will cover:
To be eligible for these scholarships applicants must: be a UK or Irish national; or have pre-settled or settled status; or have indefinite leave to remain or enter.
Applicants should also meet the residency criteria which requires that they have lived in the EEA, Switzerland, the UK or Gibraltar for at least the three years preceding the start date of the research degree programme i.e. September 2027.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year, or part-time equivalent, funded from any source, including self-financing students, are NOT eligible to apply for an award.
Students in full-time employment are not eligible for an award.
Due consideration should be given to financing your studies.
Part-time PhD scholarships may be available at a 0.5 pro rata rate of the full-time scholarship, which would require a six-year registration period.
The University will award a successful candidate one of the following scholarships for the project, depending on the funding available at the time an admissions offer is made:
Please note that the Terms and Conditions for scholarships are subject to change for 2027/28.
1.Nomikou N, McHale AP. Exploiting ultrasound-mediated effects in delivering targeted, site-specific cancer therapy. Cancer Lett. 2010 Oct 28;296(2):133-43. doi: 10.1016/j.canlet.2010.06.002. Epub 2010 Jul 3. PMID: 20598800.
2.Nesbitt H, Logan K, Thomas K, Callan B, Gao J, McKaig T, Taylor M, Love M, Stride E, McHale AP, Callan JF. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer Lett. 2021 Oct 1;517:88-95. doi: 10.1016/j.canlet.2021.06.003. Epub 2021 Jun 10. PMID: 34119606.
3.Wright J, Logan K, McKaig T, Kamila S, McClenaghan C, Nesbitt H, Taylor MA, Love M, Stride E, Ruan JL, McHale AP, Callan JF. Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic cancer. Eur J Pharm Biopharm. 2026 Jan;218:114937. doi: 10.1016/j.ejpb.2025.114937. Epub 2025 Nov 19. PMID: 41270840.
Submission deadline
Friday 8 January 2027
04:00PM
Interview Date
between 8 -16 February 2027
Preferred student start date
13 September 2027
Telephone
Contact by phone
Email
Contact by email